Tirzepatide in Early Type 2 Diabetes: SURPASS-EARLY Results

Tirzepatide improved two-year glucose and weight outcomes compared with intensified conventional care in SURPASS-EARLY, a randomized study of adults with recently diagnosed type 2 diabetes whose glucose remained inadequately controlled on metformin. The result supports discussing treatment intensification early in the disease course; it does not show that diabetes was cured.¹

The distinction matters when reading that many participants reached a normal-range HbA1c. A low HbA1c while taking medication answers a different question from sustained glucose control after medication has been withdrawn.

Who was actually studied?

The phase 4 trial randomized 794 adults at 78 sites in ten countries. Participants had type 2 diabetes for no more than four years and were taking metformin. Tirzepatide was escalated toward 15 mg or the maximum tolerated dose. The other group received intensified conventional care guided by local practice, including other GLP-1 receptor agonists but excluding tirzepatide.¹

That comparator is more informative than leaving people on an ineffective regimen, but it is also a mixture of treatment choices. This was not a dedicated trial of tirzepatide against one named medicine at one fixed dose.

The sponsor's clinical presentation clarifies that metformin continued as background therapy and describes the broader study as lasting 208 weeks, with its primary assessment at 104 weeks. The published two-year result should not be presented as a completed four-year outcome.²

What changed after two years?

In the treatment-regimen analysis, average HbA1c fell by 1.99 percentage points with tirzepatide and 1.32 percentage points with conventional care. The adjusted difference was 0.68 percentage points favoring tirzepatide. The tirzepatide group also had a greater reduction in weight, with an adjusted between-group difference of 8.0 kg, and in waist circumference, by 6.2 cm.¹

These differences describe average changes between assigned groups. They do not mean every participant lost an extra 8 kg, nor that 8 kg was the total weight reduction in the tirzepatide group. Confusing a treatment difference with an absolute result can substantially change what a reader expects.

Normal-range HbA1c does not establish remission

HbA1c below 5.7% was reached by 60.2% of tirzepatide participants and 24.0% of conventional-care participants. Those were measurements during treatment. The trial's reported endpoint was normoglycemia, not medication-free remission.¹

If your HbA1c improves, ask which medicines should continue and how glucose will be followed. Do not stop metformin, insulin or another prescribed treatment because your laboratory result crosses a threshold. The study does not provide a self-directed withdrawal schedule.

For a related but distinct question, our stopping tirzepatide guide examines what happens when treatment ends. Weight-management withdrawal evidence should also be kept separate from proof of diabetes remission.

What about side effects and low blood sugar?

The paper identifies gastrointestinal events as the most common adverse events in both groups. In the sponsor's trial presentation, severe hypoglycemia was reported in neither arm; the separate reported proportions with blood glucose below 54 mg/dL were 4.3% with tirzepatide and 3.3% with conventional care. Do not combine these categories or assume that “no severe events” means no low-glucose episodes. That observation should be read alongside the current Mounjaro label: use with insulin or an insulin secretagogue can increase hypoglycemia risk and may require clinician-directed changes to those medicines.¹²³

A trial-level zero is not a guarantee for an individual. Risk depends on accompanying medicines, intake and clinical circumstances. Our tirzepatide and hypoglycemia guide explains the distinction.

How strong is the evidence?

Random allocation strengthens the comparison. However, the study was open label: patients and treating clinicians knew the assigned strategy. Lilly funded the trial, and several authors were company employees. Those details belong alongside the results when judging how confidently to generalize them.¹

The findings apply most directly to adults similar to those enrolled. They do not establish the same benefit in type 1 diabetes, pregnancy, people with much longer-standing diabetes or people whose glucose is already adequately controlled on metformin. They also do not establish superiority over every possible contemporary combination.

A useful discussion after diagnosis

If metformin and lifestyle measures are not meeting your treatment goals, ask your clinician how tirzepatide compares with other appropriate options in your case. Bring your HbA1c trend, medication list, side-effect concerns and coverage information. Ask what would count as success and when the plan should be reassessed.

Use our Mounjaro versus Zepbound comparison to distinguish brand indications and our tirzepatide evidence guide for the wider trial program. SURPASS-EARLY adds a specific answer about earlier treatment intensification; it does not replace an individualized care plan.